Felis Catus Milk

Dosage for Felis Catus Milk is highly individualized and depends strictly on the intended clinical use.

For Diagnostic Allergy Testing

• Skin Prick Test (SPT): A single drop of the standardized extract (usually 10,000 AU/mL) is applied to the volar surface of the forearm. A sterile lancet is used to prick the skin through the drop. Results are read at 15–20 minutes.
• Intradermal Testing: If SPT is negative, a 1:100 or 1:1000 dilution of the extract may be injected intradermally (0.02 to 0.05 mL) to form a small bleb.

For Allergen Immunotherapy (SCIT)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 dilution). Doses are increased weekly or bi-weekly as tolerated by the patient until the maintenance dose is reached.
• Maintenance Phase: The target maintenance dose is usually between 0.5 mL of a 1:100 dilution to 0.5 mL of the concentrated 10,000 AU/mL vial, administered every 2 to 4 weeks.

For Nitrogen Binding (Ammonium Regulation)

• Standard Dose: While specific protocols vary, clinical studies suggest a range of 2–5 grams administered three times daily with meals to maximize the binding of dietary nitrogen and endogenous ammonium ions.

Felis Catus Milk may be used in pediatric patients under the strict supervision of a board-certified allergist or metabolic specialist.

• Allergy Testing: Pediatric dosing for SPT is identical to adult dosing; however, fewer tests may be performed simultaneously to minimize discomfort.
• Immunotherapy: Generally not recommended for children under the age of 5 due to the difficulty of communicating systemic symptoms of anaphylaxis. For children 5 and older, the build-up schedule may be more conservative (slower) than the adult schedule.
• Metabolic Use: Pediatric dosing for nitrogen binding is typically weight-based (e.g., 100–200 mg/kg/day divided into three doses).

Renal Impairment

For patients with significant renal impairment, the clearance of bound ammonium complexes may be reduced. Clinicians should monitor blood urea nitrogen (BUN) and creatinine levels closely. A dose reduction of 25–50% may be necessary in Stage 4 or 5 Chronic Kidney Disease (CKD).

Hepatic Impairment

In patients with hepatic impairment, Felis Catus Milk is often used because of its ammonium binding activity to offset the liver's inability to process ammonia. However, if the patient has severe portal hypertension, the risk of systemic absorption of allergens may increase. No specific dose adjustment is standardized, but frequent monitoring of ammonia levels is required.

Elderly Patients

Elderly patients may have a reduced skin response to allergy testing. For immunotherapy, the presence of comorbid cardiovascular conditions (e.g., use of beta-blockers) may necessitate a more cautious dosing approach due to the increased risk and difficulty in treating anaphylaxis.

• Injections: Must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment (epinephrine, oxygen, IV fluids). Patients must remain in the office for at least 30 minutes post-injection.
• Oral Forms: If prescribed for nitrogen binding, Felis Catus Milk should be taken with meals to ensure it interacts with nitrogenous components of food. Do not crush or chew capsules if provided in an enteric-coated form.
• Storage: Most liquid extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the proteins and alter potency.

• Immunotherapy: If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay. If the delay is more than 4 weeks, the physician may restart the build-up from a lower concentration.
• Nitrogen Binding: Take the missed dose as soon as remembered, unless it is almost time for the next dose. Do not double the dose.

• Signs of Overdose: Excessive local swelling at the injection site, generalized hives (urticaria), angioedema (swelling of the face/throat), wheezing, hypotension, and in extreme cases, cardiac arrest.
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3 mg for adults), followed by antihistamines, corticosteroids, and supportive care. For oral overdose, gastric lavage may be considered if caught early.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without direct medical guidance, as this increases the risk of life-threatening allergic reactions.

Side effects associated with Felis Catus Milk are most frequent when the agent is used as an allergenic extract.

• Local Injection Site Reactions: More than 90% of patients receiving immunotherapy will experience some degree of redness, itching, or swelling at the site of injection. This typically appears within 30 minutes and subsides within 24 hours.
• Wheal and Flare: During diagnostic testing, a positive reaction is technically a 'side effect' of the IgE interaction, characterized by a raised, itchy bump similar to a mosquito bite.
• Gastrointestinal Distress: When used as a nitrogen binding agent, common effects include mild nausea, bloating, or flatulence as the agent interacts with the gut microbiota.

• Large Local Reactions (LLRs): Swelling that exceeds 5-10 cm in diameter at the injection site. This may be accompanied by warmth and significant discomfort.
• Systemic Urticaria: Hives appearing on parts of the body away from the injection site.
• Rhinitis: Sneezing, nasal congestion, or a runny nose shortly after administration.
• Headache: A dull, aching sensation reported by some patients following immunotherapy sessions.

• Delayed Reactions: Swelling or flu-like symptoms that occur 6 to 24 hours after the dose.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the axilla/armpit).
• Hypocalcemia: In its role as a nitrogen binder, the agent may inadvertently bind other cations, potentially leading to a slight decrease in serum calcium levels.

> Warning: Stop taking Felis Catus Milk and call your doctor immediately if you experience any of these symptoms. These may indicate a life-threatening systemic reaction (anaphylaxis).

• Anaphylaxis: A rapid-onset, multi-system allergic reaction. Signs include a drop in blood pressure, loss of consciousness, and severe respiratory distress.
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Sudden constriction of the muscles in the walls of the bronchioles, causing severe wheezing and inability to catch one's breath.
• Cyanosis: A bluish discoloration of the skin or mucous membranes, indicating insufficient oxygenation.
• Seizures: Though extremely rare, systemic toxicity or severe hypoxia from an allergic reaction can trigger seizure activity.

• Immune System Alteration: While the goal of immunotherapy is to alter the immune system for the better, long-term use can occasionally lead to the development of new sensitivities or, very rarely, autoimmune-like phenomena, though a causal link is not firmly established.
• Renal Stress: Prolonged use as a nitrogen binder requires ongoing monitoring of kidney function to ensure that the excretion of bound complexes does not lead to tubular strain.

Felis Catus Milk, when used as a standardized allergenic extract, carries a Black Box Warning regarding the risk of severe anaphylaxis.

Summary of Warning:

1. 1Felis Catus Milk can cause severe, life-threatening systemic allergic reactions, including anaphylaxis.
2. 2It should only be administered by healthcare professionals trained in the management of anaphylaxis.
3. 3Patients with unstable asthma are at a significantly higher risk for fatal reactions.
4. 4Patients must be observed for at least 30 minutes following every injection.
5. 5The product may not be suitable for patients taking beta-blockers, as they may be unresponsive to the usual doses of epinephrine used to treat anaphylaxis.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Adverse events can also be reported to the FDA MedWatch program.

Felis Catus Milk is a potent biological agent that must be handled with extreme caution. It is not a standard medication for self-administration unless specifically instructed in an autoinjectable format for maintenance (which is rare). The primary risk associated with this agent is the unpredictable nature of hypersensitivity reactions. Every patient, regardless of their previous tolerance, is at risk for a systemic reaction with any given dose.

No FDA black box warnings for Felis Catus Milk when used specifically as a nitrogen binder; however, as a Standardized Allergenic Extract, it carries the following mandate:

"Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylactic shock and death. This product must be administered in a facility equipped to treat such reactions. Patients must be monitored for 30 minutes post-injection. Do not administer to patients with severe or unstable asthma."

• Allergic Reactions / Anaphylaxis Risk: This is the most significant risk. Anaphylaxis can occur within minutes and involve the skin, respiratory, cardiovascular, and gastrointestinal systems. Risk factors include a high level of sensitivity, rapid dose escalation, and administration during peak allergy seasons.
• Asthma Exacerbation: Patients with pre-existing asthma must have their condition well-controlled before receiving Felis Catus Milk. A peak flow meter may be used to assess lung function before each dose. If the peak flow is significantly below the patient's personal best, the dose should be withheld.
• Cardiovascular Stress: The systemic release of mediators during a reaction can place significant stress on the heart. Patients with a history of myocardial infarction, unstable angina, or severe hypertension should only use Felis Catus Milk if the benefits clearly outweigh the risks.
• Nitrogen Imbalance: When used for its ammonium ion binding activity, there is a risk of inducing an electrolyte imbalance. Specifically, the binding of ammonium may affect the balance of other cations like sodium and potassium.

Patients undergoing treatment with Felis Catus Milk require regular clinical assessment:

• Symptom Review: Assessment of any 'late-phase' reactions from the previous dose.
• Lung Function: Pulmonary function tests (PFTs) or peak flow monitoring for asthmatic patients.
• Metabolic Panels: If used as a nitrogen binder, regular monitoring of serum ammonia, BUN, creatinine, and electrolytes (sodium, potassium, calcium) is mandatory.
• Injection Site Inspection: Checking for the development of nodules or persistent LLRs.

Felis Catus Milk itself does not typically cause sedation. However, if a systemic reaction occurs, or if antihistamines are administered to treat a local reaction, the patient may experience drowsiness. Patients should not drive or operate heavy machinery for at least 1-2 hours after an injection to ensure no delayed systemic symptoms develop.

Alcohol consumption should be avoided on the day of an injection. Alcohol causes vasodilation (widening of blood vessels), which can potentially increase the rate of allergen absorption from the injection site and exacerbate the severity of an allergic reaction.

• Immunotherapy: Discontinuation can usually be done abruptly without a withdrawal syndrome. However, the patient's allergy symptoms will likely return over time.
• Nitrogen Binding: If used for hyperammonemia, stopping Felis Catus Milk suddenly can lead to a rapid rise in systemic ammonia levels, potentially triggering a metabolic crisis or encephalopathy. Tapering is generally not required, but alternative therapies must be in place.

> Important: Discuss all your medical conditions, especially respiratory and heart problems, with your healthcare provider before starting Felis Catus Milk.

• Beta-Adrenergic Blockers (Beta-Blockers): (e.g., Propranolol, Atenolol, Metoprolol). These medications are contraindicated in patients receiving Felis Catus Milk injections. Beta-blockers can increase the severity of anaphylaxis and, more importantly, they block the effects of epinephrine (adrenaline), which is the primary treatment for a life-threatening reaction. Using these together can make an allergic reaction untreatable.

• ACE Inhibitors: (e.g., Lisinopril, Enalapril). These may increase the risk of systemic reactions or angioedema during immunotherapy. The mechanism is thought to involve the inhibition of bradykinin breakdown.
• MAO Inhibitors (MAOIs): (e.g., Phenelzine, Selegiline). These can potentiate the effects of sympathomimetics used to treat reactions, leading to hypertensive crises.
• Tricyclic Antidepressants: May also interfere with the management of a systemic reaction.

• Antihistamines: (e.g., Cetirizine, Loratadine, Diphenhydramine). While often used to treat side effects, taking antihistamines before a diagnostic skin test will cause a false-negative result by masking the wheal and flare reaction. These should be discontinued 3–7 days prior to testing.
• Corticosteroids: Long-term systemic steroids may suppress the immune response to the extract, potentially reducing the efficacy of immunotherapy or masking diagnostic results.

• High-Protein Meals: If Felis Catus Milk is being used as a Nitrogen Binding Agent, a very high protein intake may overwhelm the agent's capacity to bind ammonium, leading to elevated ammonia levels despite treatment.
• Alcohol: As mentioned, alcohol can increase the risk of systemic absorption and vasodilation during immunotherapy.

• St. John’s Wort: While no direct metabolic interaction exists, its potential to affect vascular tone should be considered.
• Cationic Supplements: Supplements containing high doses of Calcium, Magnesium, or Zinc may compete with ammonium for the binding sites on Felis Catus Milk when used as a nitrogen binder, reducing its effectiveness.

• Skin Tests: Interference by H1-antagonists (antihistamines) and certain antidepressants.
• Ammonia Assays: The presence of the binding agent in the blood may interfere with certain enzymatic ammonia assays, potentially giving falsely low readings. Clinicians should use alternative methods if interference is suspected.

Interaction Mechanism Summary

• Pharmacodynamic Interaction: Beta-blockers and epinephrine (antagonism of the rescue medication).
• Pharmacokinetic Interaction: Cation competition in the gut (reduced ammonium binding).
• Clinical Consequence: Increased risk of fatal anaphylaxis or reduced control of hyperammonemia.
• Management Strategy: Discontinue beta-blockers if possible before starting AIT; space out cationic supplements from nitrogen-binding doses.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.

Felis Catus Milk must NEVER be used in the following circumstances:

1. 1Severe, Unstable, or Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted values are at an unacceptably high risk for fatal bronchospasm during treatment.
2. 2Recent Myocardial Infarction or Unstable Angina: The physiological stress of a systemic reaction and the subsequent administration of epinephrine can be fatal in patients with compromised cardiac function.
3. 3History of Severe Anaphylaxis to Felis Catus Products: If a patient has previously experienced a near-fatal reaction to cat-derived extracts, the risk of re-challenge often outweighs any diagnostic or therapeutic benefit.
4. 4Concurrent Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis with epinephrine.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with allergenic extracts could exacerbate conditions like Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis.
• Malignancy: Patients with active cancer may have altered immune profiles that make immunotherapy less predictable.
• Severe Atopic Dermatitis: May make the interpretation of skin tests difficult and increase the risk of systemic absorption.
• Pregnancy: While not an absolute contraindication for continuing maintenance therapy, it is generally contraindicated to start Felis Catus Milk therapy during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia.

Patients sensitive to Felis Catus Milk may also show cross-reactivity with:

• Other Feline Species: Extracts from lions, tigers, or cougars.
• Porcine Serum Albumin: Known as the 'pork-cat syndrome,' where patients allergic to cat albumin (Fel d 2) react to pork meat.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Felis Catus Milk.

FDA Pregnancy Category C.

There are no adequate and well-controlled studies of Felis Catus Milk in pregnant women. Animal reproduction studies have not been conducted.

• Risk Summary: The primary risk to the fetus is maternal anaphylaxis, which can lead to uterine contractions, placental hypoperfusion, and fetal hypoxia (lack of oxygen).
• Clinical Considerations: It is generally recommended that Felis Catus Milk immunotherapy NOT be initiated during pregnancy. However, if a patient is already on a stable maintenance dose and becomes pregnant, the physician may choose to continue the dose without further escalation, as the risk of a reaction is lower during maintenance.

It is not known whether the allergenic proteins or the nitrogen-binding components of Felis Catus Milk are excreted in human milk.

• Risk-Benefit: Because these are large proteins that are likely digested in the infant's gastrointestinal tract, the risk to the nursing infant is considered low. However, the mother should be monitored for systemic reactions that could interfere with her ability to breastfeed.

• Approved Age: Felis Catus Milk is used in children as young as 5 years for immunotherapy.
• Special Considerations: Children have a higher surface-area-to-mass ratio, which may affect the speed of systemic absorption. The primary challenge in pediatrics is the child's inability to articulate early symptoms of a reaction (e.g., 'itchy throat' or 'sense of doom').
• Growth Effects: There is no evidence that Felis Catus Milk affects growth or development in children.

• Safety Profile: Patients over 65 may have a higher prevalence of cardiovascular disease, making them more vulnerable to the effects of a systemic reaction.
• Pharmacokinetics: Reduced renal clearance in the elderly may necessitate lower doses when Felis Catus Milk is used as a nitrogen binding agent.
• Polypharmacy: The high likelihood of elderly patients taking beta-blockers or ACE inhibitors requires a thorough medication review.

In patients with a GFR < 30 mL/min/1.73m², the use of Felis Catus Milk as a nitrogen binder should be approached with caution. While the agent itself may not be nephrotoxic, the altered electrolyte balance (potential for hyperkalemia or hypocalcemia) must be managed. Dialysis does not significantly clear the allergenic proteins but may clear the bound ammonium complexes.

Felis Catus Milk is often indicated in hepatic impairment (Child-Pugh Class B and C) to assist in ammonia clearance. However, clinicians must be vigilant for signs of hepatorenal syndrome, which would complicate the clearance of the nitrogenous complexes.

> Important: Special populations require individualized medical assessment and more frequent monitoring by a specialist.

Felis Catus Milk functions via two distinct molecular pathways:

1. 1Immunological Pathway: The active allergenic proteins (primarily Fel d 1 and Fel d 4) bind to bivalent IgE molecules on the surface of mast cells. In diagnostic use, this causes immediate mediator release. In therapeutic use (immunotherapy), it induces the production of IL-10-producing regulatory T-cells, which shift the immune system away from an allergic Th2 response. This leads to a decrease in allergen-specific IgE and an increase in allergen-specific IgG4, which acts as a 'decoy' or blocking antibody.

1. 1Metabolic Pathway (Nitrogen Binding): The agent possesses Ammonium Ion Binding Activity. It acts as a molecular scaffold with high affinity for the NH4+ cation. By sequestering ammonium in the intestinal lumen or systemic circulation, it prevents the conversion of nitrogenous waste into toxic ammonia (NH3), thereby facilitating the excretion of nitrogen via the feces or urine as a stable complex.

• Onset of Effect: For diagnostic testing, the onset is rapid (15–20 minutes). For immunotherapy, clinical improvement in symptoms typically requires 6–12 months of consistent treatment. For nitrogen binding, ammonia levels may begin to decrease within 24–48 hours of starting therapy.
• Duration of Effect: The desensitization effect of immunotherapy can last for years after a 3–5 year course of treatment. The nitrogen-binding effect is transient and lasts only as long as the drug is present in the system.

| Parameter | Value |

|---|---|

| Bioavailability | < 5% (Subcutaneous/Epicutaneous); Variable (Oral) |

| Protein Binding | N/A (Is a protein itself) |

| Half-life | 2–4 hours (Initial phase); 24+ hours (Terminal phase) |

| Tmax | 30–60 minutes (Subcutaneous) |

| Metabolism | Proteolysis (Degradation by proteases) |

| Excretion | Renal (60%), Fecal (40% as bound complex) |

• Molecular Formula: Complex biological mixture; primary allergen Fel d 1 is a tetrameric glycoprotein (approx. 35 kDa).
• Solubility: Highly soluble in aqueous buffered solutions; often formulated in 50% glycerin for stability.
• Structure: Consists of two heterodimers, each containing two chains (Chain 1 and Chain 2) linked by disulfide bonds.

Felis Catus Milk is categorized as a Standardized Chemical Allergen and a Nitrogen Binding Agent. It is related to other animal-derived allergenic extracts (e.g., Canis familiaris extract) and other nitrogen binders like Sodium Phenylbutyrate, though its mechanism of direct ammonium binding is distinct.